CSIMarket Company Name, Ticker, Competitors, else..
 
Bio techne Corp  (NASDAQ: TECH)
Other Ticker:  
 
 
Price: $50.5000 $0.25 0.498%
Day's High: $50.7542 Week Perf: 0.68 %
Day's Low: $ 49.55 30 Day Perf: -14.95 %
Volume (M): 1,335 52 Wk High: $ 85.57
Volume (M$): $ 67,438 52 Wk Avg: $71.59
Open: $50.21 52 Wk Low: $46.44



 Market Capitalization (Millions $) 8,112
 Shares Outstanding (Millions) 161
 Employees 3,100
 Revenues (TTM) (Millions $) 1,175
 Net Income (TTM) (Millions $) 115
 Cash Flow (TTM) (Millions $) 29
 Capital Exp. (TTM) (Millions $) 65

Bio Techne Corp
Bio-Techne Corporation is a global life sciences company whose mission is to provide innovative, high-quality scientific tools and resources to researchers in diagnostics and therapeutics.
The company was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne operates through four divisions: Protein Platforms, Diagnostics & Genomics, Cell & Gene Therapy, and Clinical Controls.
The Protein Platforms division provides innovative protein analysis tools and technologies to researchers in academic and biopharmaceutical industries.
This includes single-cell proteomics, mass spectrometry, and western blotting among others.
The Diagnostics & Genomics division offers diagnostic kits and reagents for clinical and research markets, including ELISAs, cell culture products, and RNA analysis tools.
The Cell & Gene Therapy division provides innovative solutions for the development and production of cell and gene therapies.
This includes T cell activation reagents, gene editing tools, and viral vector systems among others.
The Clinical Controls division specializes in the production of quality controls and calibrators for clinical laboratories.
These products are used for monitoring the accuracy and precision of laboratory testing procedures.
Bio-Techne operates globally and serves a diverse customer base including biopharmaceutical companies, academic and government institutions, clinical research organizations, and diagnostic laboratories.
The company's dedication to research and development, customer support, and quality control has earned it a reputation of excellence in the life sciences industry.
Bio-Techne has over 3,000 employees worldwide and is committed to advancing science by providing innovative solutions and technologies for researchers and clinicians alike.


   Company Address: 614 McKinley Place N.E. Minneapolis 55413 MN
   Company Phone Number: 379-8854   Stock Exchange / Ticker: NASDAQ TECH


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
QGEN        0.73% 
RGEN   -7.11%    
TWST        5.48% 
A        0.53% 
BIO   -2.62%    
ILMN        1.11% 
• View Complete Report
   



Bio Techne Corp

Bio Techne Corp faces earnings decline amidst revenue growth in Q2 2024

As a Wall Street journalist, it is clear that Bio Techne Corp has faced significant challenges in the second quarter of 2024. Despite a slight increase in revenue, the company experienced a substantial decline in income, with profits plummeting by -45.16% compared to the same period a year ago. This is a concerning trend for investors and indicates that the company may be struggling to maintain profitability in the competitive Biotechnology & Pharmaceuticals sector.
One of the key factors contributing to Bio Techne Corp's poor performance is a shift in focus towards improving sales, which has resulted in a decrease in net margin to 10.08%. Additionally, the company's operating earnings fell by -44.02%, squeezing its operating margin to 13.94%. These financial indicators suggest that Bio Techne Corp may be facing pressure to increase sales at the expense of profitability.
Bio Techne Corp

Bio Techne Corp Reports Revenue Surge in Q3 2023, Despite Downturn in Earnings



Bio Techne Corp, a leading biotechnology company, recently released its financial results for the most recent fiscal period, ending on September 30, 2023. The results showed a modest improvement in revenue, but a significant decline in income compared to the same period a year earlier. This article will outline the key facts and analyze the implications of these financial results. Additionally, it will provide context by considering the company's recent share performance.
Revenue and Income Performance:
During the most recent fiscal period, Bio Techne Corp recorded revenue of $276.19 million, representing a marginal decline of -8.387% compared to the prior reporting period. However, in a year-over-year comparison, revenue improved by 2.447%. Despite this revenue improvement, the company experienced a notable decline in income, with a drop of -85.97% relative to the comparable reporting period a year before. Net profits for the period amounted to $50.993 million, reflecting a decrease of -43.17% compared to the corresponding period a year ago.
Bio Techne Corp

Bio Techne Corp Shocks Market with Astonishing 87% Plummet in Earnings, Despite Impressive Revenue Surge

Bio Techne Corp, a leading biotechnology and pharmaceuticals company, recently reported its financial results for the most recent fiscal period. While its revenue increased by 4.597% to $301.48 million compared to $288.23 million in the previous year, its earnings per share (EPS) saw a sharp decline of -87.62% to $0.19 per share. This is a significant decrease from the $1.51 per share reported in the same period last year.
Many were surprised by Bio Techne Corp's performance as it achieved revenue growth while other companies in the biotechnology and pharmaceuticals industry experienced a contraction of -13.05% in their business. In the previous reporting period, the company recorded revenue of $293.16 million and a bottom line of $0.43 per share.
Bio Techne Corp

Bio Techne Corp Reports Modest Revenue Growth of 1.298% in Q3 2023, but Declining Net Income Raises Concerns

Investing in the stock market can be a tempting opportunity but requires a prudent approach to evaluate the performance of a company. The financial report of Bio Techne Corp in the third quarter of 2023 presents a mixed picture. While the revenue rose by 1.298%, the net income declined by -70.95% compared to the same period a year ago. Furthermore, the operating margin fell to 27.27%, reflecting a decline in operating earnings by -11.32%.
Despite the increase in net income of $70.218 million in the fiscal span closing March 31 2023, which is a positive sign, investors need to be cautious. The company's income demise of -70.95% could indicate that the company is struggling to maintain profitability. It is crucial to evaluate the company's financial health carefully before making any investment decisions.






Bio Techne's Segments
United States    53.86 % of total Revenue
EMEA excluding United Kingdom    23.71 % of total Revenue
United Kingdom    4.46 % of total Revenue
APAC excluding Greater China    6.4 % of total Revenue
Greater China    8.34 % of total Revenue
Rest of World    3.28 % of total Revenue
Consumables    77.71 % of total Revenue
Instruments    10.4 % of total Revenue
Services    9.21 % of total Revenue
Product and Services    97.32 % of total Revenue
Royalty revenues    2.73 % of total Revenue
Other Revenues from Business Held for Sale    0.62 % of total Revenue
Protein Sciences    71.26 % of total Revenue
Diagnostics and Spatial Biology    28.34 % of total Revenue
InterEliminations    -0.17 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com